Kymera CFO exercises options for 12,653 KYMR shares

Kymera Therapeutics, Inc. Chief Financial Officer Bruce N. Jacobs exercised stock options to acquire 12,653 shares of common stock at an exercise price of $2.08 per share.

Accepted by SEC EDGAR 06/03/2026 - 07:30 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. Chief Financial Officer Bruce N. Jacobs exercised stock options to acquire 12,653 shares of common stock at an exercise price of $2.08 per share. The corresponding stock option for 12,653 shares was fully exercised and now shows zero derivative shares remaining. Following this transaction, Jacobs holds 260,241 shares of Kymera Therapeutics common stock directly, with no related sale or tax-withholding disposition reported in this filing.

Insider Trade Summary

12,653 shares exercised/converted

Exercise 2 txns

Insider Jacobs Bruce N.

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	12,653	$0.00	$0.00
Exercise	Common Stock	12,653	$2.08	$26K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 260,241 shares (Direct)

Holdings Before and After: Stock Option (Right to Buy), 12,653 to 0 contracts (Direct); Common Stock, 247,588 to 260,241 shares (Direct)

Footnotes (1)

1. F1. The shares underlying this stock option are fully vested and exercisable.

Key Figures

Options exercised: 12,653 shares Exercise price: $2.08 per share Shares held after: 260,241 shares +2 more

5 metrics

Options exercised 12,653 shares Common stock acquired via option exercise

Exercise price $2.08 per share Strike price of exercised stock option

Shares held after 260,241 shares Direct common stock holdings after transaction

Exercised option size 12,653 shares Stock Option (Right to Buy) fully exercised

Option expiration August 28, 2029 Expiration date of the exercised option grant

Key Terms

Stock Option (Right to Buy), derivative security, fully vested and exercisable

3 terms

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

fully vested and exercisable financial

"The shares underlying this stock option are fully vested and exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Kymera Therapeutics (KYMR) report for Bruce N. Jacobs?

Kymera Therapeutics reported that CFO Bruce N. Jacobs exercised stock options for 12,653 shares of common stock. This increased his directly held stake, with no sale reported in this Form 4.

How many Kymera Therapeutics (KYMR) shares does the CFO hold after this Form 4?

After exercising options, CFO Bruce N. Jacobs holds 260,241 shares of Kymera Therapeutics common stock directly. This figure reflects his position immediately following the reported transaction on the Form 4.

At what price did the Kymera Therapeutics (KYMR) CFO exercise his stock options?

Bruce N. Jacobs exercised his Kymera Therapeutics stock options at an exercise price of $2.08 per share. The transaction involved 12,653 underlying common shares acquired through this fully vested option.

Did the Kymera Therapeutics (KYMR) Form 4 show any share sales by the CFO?

The Form 4 does not report any sales by CFO Bruce N. Jacobs. It only shows the exercise of a stock option for 12,653 common shares, with no open-market sale or tax-withholding disposition disclosed.

What happened to the exercised Kymera Therapeutics (KYMR) stock option after the transaction?

The stock option covering 12,653 Kymera Therapeutics shares was fully exercised, leaving zero derivative shares outstanding under that grant. A footnote states the underlying shares were fully vested and exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jacobs Bruce N.

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/02/2026		M		12,653	A	$2.08	260,241	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.08	06/02/2026		M			12,653	(1)	08/28/2029	Common Stock	12,653	$0	0	D

Explanation of Responses:

1. The shares underlying this stock option are fully vested and exercisable.

	/s/ Bruce N. Jacobs	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)